Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-3.48% $3.05
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 54.87 mill |
EPS: | -0.410 |
P/E: | -7.44 |
Earnings Date: | Aug 10, 2023 |
SharesOutstanding: | 17.99 mill |
Avg Daily Volume: | 0.0489 mill |
RATING 2024-04-18 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -7.44 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.27x |
Company: PE -7.44 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.575 (-81.13%) $-2.47 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 2.44 - 3.67 ( +/- 20.16%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.05 (-3.48% ) |
Volume | 0.0306 mill |
Avg. Vol. | 0.0489 mill |
% of Avg. Vol | 62.52 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.